Skip to main content
. 2018 Jan 18;17(3):4307–4316. doi: 10.3892/mmr.2018.8461

Figure 2.

Figure 2.

Effect of autophagy modulators on the viability of DEX-treated cells. (A) Cells were treated with DEX (10−8 M) or DEX (10−8 M + 3-MA (5 mM) for 0, 24, 48 or 72 h, and cell viability was estimated using the MTT assay. (B) Quantification analysis of apoptotic cells in 3-MA studies. (C) Apoptosis among cells treated with DEX (10−8 M) or DEX (10−8 M) + 3-MA (5 mM) for 24 h was estimated using Annexin V-FITC/PI staining. (D) Apoptosis among cells treated with DEX (10−6 M) or DEX (10−6 M) + Rap (3 µM) for 24 h was estimated using Annexin V-FITC/PI staining. (E) Quantification analysis of apoptotic cells in Rap studies. (F) Cells were treated with DEX (10−6 M) or DEX (10−6 M) + Rap (3 µM) for 0, 24, 48 or 72 h, and cell viability was then estimated using the MTT assay. Viable cells, early apoptotic cells, late apoptotic cells and necrotic cells appear in the bottom left quadrant (Q3), bottom right quadrant (Q4), top right quadrant (Q2) and top left quadrant (Q1), respectively. The apoptotic rate was determined as the percentage of Q2 + Q4. Values are presented as the mean ± standard deviation from three independent experiments. *P<0.05 vs. control group; #P<0.05 vs. DEX only group. FITC, fluorescein isothiocyanate; PI, propidium iodide; DEX, dexamethasone; Rap, rapamycin; 3-MA, 3-methyladenine.